Proteins: emerging carrier for delivery of cancer therapeutics

Bibliography

• Atkins JH, Gershell LJ. Selective anticancer drugs. Nat Rev Drug Discov 2002;1:491-2
   PubMed Web of Science ®Google Scholar
• Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971;8:871-4
   PubMedGoogle Scholar
• Naor D, Galili N. Immune response to chemically modified antigens. Prog Allergy 1977;22:107-46
   PubMedGoogle Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83
   PubMed Web of Science ®Google Scholar
• Andrady C, Sharma SK, Chester KA. Antibody-enzyme fusion proteins for cancer therapy. Immunotherapy 2011;3:193-211
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• Fiume L, Bolondi L, Busi C, et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol 2005;43:645-52
   PubMed Web of Science ®Google Scholar
• Lee M-S, Jung J-I, Kwon S-H, et al. TIMP-2 Fusion protein with human serum albumin potentiates anti-angiogenesis-mediated inhibition of tumor growth by suppressing MMP-2 Expression. PLoS One 2012;7:e35710
   Google Scholar
• Gatter KC, Brown G, Trowbridge I, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45
   PubMed Web of Science ®Google Scholar
• Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis 2007;39:82-91
   PubMed Web of Science ®Google Scholar
• Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312:162-3
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu L, Yin Q, et al. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release 2012;159:429-34
   PubMed Web of Science ®Google Scholar
• Gao HL, Pang ZQ, Fan L, et al. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol Sin 2010;31:237-43
   PubMed Web of Science ®Google Scholar
• Yeh CJ, Faulk WP. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin Immunol Immunopathol 1984;32:1-11
   PubMedGoogle Scholar
• Sizensky JA, Barabas K, Faulk WP. Characterization of the anti-cancer activity of transferrin-adriamycin conjugates. Am J Reprod Immunol 1992;27:163-6
   PubMed Web of Science ®Google Scholar
• Singh M, Atwal H, Micetich R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res 1998;18:1423-7
   PubMed Web of Science ®Google Scholar
• Kratz F, Beyer U, Roth T, et al. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J Pharm Sci 1998;87:338-46
   PubMed Web of Science ®Google Scholar
• Stjernholm RL. Platinum bound to transferrin for use in the treatment of breast tumors. US4590001; 1986
   Google Scholar
• Shin SU, Friden P, Moran M, et al. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 1995;92:2820-4
   PubMed Web of Science ®Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70
   PubMed Web of Science ®Google Scholar
• Cho S, Byun Y. Gelatin-mPEG-Doxorubicin conjugates for the targeting delivery based on angiogenesis. 31st Korean Society of Pharmaceutics annual meeting; 2001; Seoul, Korea
   Google Scholar
• Kushibiki T, Tomoshige R, Iwanaga K, et al. Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine compounds. J Control Release 2006;112:249-56
   PubMed Web of Science ®Google Scholar
• Fukunaka Y, Iwanaga K, Morimoto K, et al. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J Control Release 2002;80:333-43
   PubMed Web of Science ®Google Scholar
• Kushibiki T, Tomoshige R, Fukunaka Y, et al. In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release 2003;90:207-16
   PubMed Web of Science ®Google Scholar
• Kushibiki T, Matsumoto K, Nakamura T, et al. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 2004;11:1205-14
   PubMed Web of Science ®Google Scholar
• Beck A, Haeuw JF, Wurch T, et al. The next generation of antibody-drug conjugates comes of age. Discov Med 2010;10:329-39
   PubMed Web of Science ®Google Scholar
• Lash A. Antibody-drug conjugates: the next generation of moving parts. Start Up 2011;1-6
   Google Scholar
• Hamblett KJ, Senter PD, Chace DF, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clin Cancer Res 2004;10:7063-70
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotech 2008;26:925-32
   PubMed Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int J Pharm 2007;337:346-56
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59
   PubMed Web of Science ®Google Scholar
• Kaul G, Amiji M. Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res 2002;19:1061-7
   PubMed Web of Science ®Google Scholar
• Singh HD, Wang G, Uludag H, et al. Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics. Acta Biomater 2010;6:4277-84
   PubMed Web of Science ®Google Scholar
• Abbasi S, Paul A, Shao W, et al. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv 2012;2012:686108
   Google Scholar
• Shen ZY, Ma GH, Dobashi T, et al. Preparation and characterization of thermo-responsive albumin nanospheres. Int J Pharm 2008;346:133-42
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Mumper RJ. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int J Pharm 2003;251:85-97
   PubMed Web of Science ®Google Scholar
• Shen Z, Li Y, Kohama K, et al. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol Res 2011;63:51-8
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhao X, Zu Y, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 2010;5:669-77
   PubMed Web of Science ®Google Scholar
• Tang QS, Chen DZ, Xue WQ, et al. Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo. Int J Nanomedicine 2011;6:3077-85
   PubMed Web of Science ®Google Scholar
• Wartlick H, Michaelis K, Balthasar S, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004;12:461-71
   PubMed Web of Science ®Google Scholar
• Steinhauser IM, Langer K, Strebhardt KM, et al. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials 2008;29:4022-8
   PubMed Web of Science ®Google Scholar
• Wagner S, Rothweiler F, Anhorn MG, et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010;31:2388-98
   PubMed Web of Science ®Google Scholar
• Balthasar S, Michaelis K, Dinauer N, et al. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005;26:2723-32
   PubMed Web of Science ®Google Scholar
• Bello L, Zhang J, Nikas DC, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas. Neurosurgery 2000;47:1185-95
   PubMed Web of Science ®Google Scholar
• Dubey PK, Singodia D, Verma RK, et al. RGD modified albumin nanospheres for tumour vasculature targeting. J Pharm Pharmacol 2011;63:33-40
   PubMed Web of Science ®Google Scholar
• Karmali PP, Kotamraju VR, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009;5:73-82
   PubMed Web of Science ®Google Scholar
• Magadala P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J 2008;10:565-76
   PubMed Web of Science ®Google Scholar
• Tseng CL, Wang TW, Dong GC, et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007;28:3996-4005
   PubMed Web of Science ®Google Scholar
• Stehle G, Wunder A, Sinn H, et al. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer drugs 1997;8:835-44
   PubMed Web of Science ®Google Scholar
• Hartung G, Stehle G, Sinn H, et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res 1999;5:753-9
   PubMed Web of Science ®Google Scholar
• Vis A, Van Der Gaast A, Van Rhijn B, et al. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 2002;49:342-5
   PubMed Web of Science ®Google Scholar
• Bolling C, Graefe T, Lübbing C, et al. Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 2006;24:521-7
   PubMed Web of Science ®Google Scholar
• Drevs J, Hofmann I, Marme D, et al. In vivo and in vitro efficacy of an acid-sensitive albumin conjugate of adriamycin compared to the parent compound in murine renal-cell carcinoma. Drug Deliv 1999;6:89-95
   Web of Science ®Google Scholar
• Schmid B, Warnecke A, Fichtner I, et al. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library. Bioconjug Chem 2007;18:1786-99
   Google Scholar
• Lebrecht D, Geist A, Ketelsen UP, et al. The 6‐maleimidocaproyl hydrazone derivative of doxorubicin (DOXO‐EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 2007;120:927-34
   PubMed Web of Science ®Google Scholar
• Unger C, Haring B, Medinger M, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 2007;13:4858-66
   PubMed Web of Science ®Google Scholar
• Elliott RL, Stjernholm R, Elliott MC. Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. Cancer Detect Prev 1988;12:469-80
   PubMedGoogle Scholar
• Faulk W, Taylor C, Yeh C, et al. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol Biother 1990;2:57-60
   PubMedGoogle Scholar
• Lai H, Nakase I, Lacoste E, et al. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res 2009;29:3807-10
   PubMed Web of Science ®Google Scholar
• Bicamumpaka C, Page M. In vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells. Oncol Rep 1998;5:1381-3
   PubMed Web of Science ®Google Scholar
• Maeda H, Edo K, Ishida N. Neocarzinostatin: the past, present, and future of an anticancer drug. Springer; Berlin: 1997
   Google Scholar
• Edmondson HA, Peters RL. Neoplasms of the liver. In: Schiff L, Schiff E, editors, Diseases of the liver. JB Lippincott, Philadelphia; 1982. p. 1101-48
   Google Scholar
• Okusaka T, Okada S, Ishii H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 1998;55:276-83
   PubMed Web of Science ®Google Scholar
• Taguchi T, Saito T, Ota J, et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881. Gan To Kagaku Ryoho Cancer Chemother 1991;18:1665-75
   PubMedGoogle Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
   PubMed Web of Science ®Google Scholar
• Guan Z, Feng F, Li Q, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25:1038
   PubMed Web of Science ®Google Scholar
• Desai N, Nab Technology - A. Drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Deliv Report Winter 2007;2008:37-41
   Google Scholar
• Porter PL, Sage EH, Lane TF, et al. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995;43:791-800
   PubMed Web of Science ®Google Scholar
• Burger AM, Hartung G, Stehle G, et al. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 2001;92:718-24
   PubMed Web of Science ®Google Scholar
• Dosio F, Brusa P, Crosasso P, et al. Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate. J Control Release 1997;47:293-304
   Web of Science ®Google Scholar
• Dosio F, Arpicco S, Stella B, et al. Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm 2009;382:117-23
   PubMed Web of Science ®Google Scholar
• Hatano T, Ohkawa K, Matsuda M. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro. Tumour Biol 1993;14:288-94
   PubMed Web of Science ®Google Scholar
• Takahashi N, Asakura T, Ohkawa K. Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells. Anticancer drugs 1996;7:687-96
   PubMed Web of Science ®Google Scholar
• Cho S, Park K, Kim SY, et al. Gelatin-MPEG-doxorubicin conjugates for the targeting delivery based on angiogenesis. 29th Annual Meeting of the Controlled Release Society Proceedings; 2002; Seoul, Korea
   Google Scholar
• Lai H, Sasaki T, Singh NP, et al. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci 2005;76:1267-79
   PubMed Web of Science ®Google Scholar
• Lai H, Nakase I, Lacoste E, et al. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res 2009;29:3807-10
   PubMed Web of Science ®Google Scholar
• Indira Chandran V, Matesic L, Locke JM, et al. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett 2012;316:151-6
   PubMed Web of Science ®Google Scholar
• Jiang YY, Liu C, Hong MH, et al. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem 2007;18:41-9
   PubMed Web of Science ®Google Scholar
• Sato Y, Yamauchi N, Takahashi M, et al. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J 2000;14:2108-18
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kaneo Y, Miyashita M. Synthesis of transferrin-mitomycin C conjugate as a receptor-mediated drug targeting system. Biol Pharm Bull 1996;19:774-7
   PubMed Web of Science ®Google Scholar
• Hoshino T, Misaki M, Yamamoto M, et al. Receptor-binding, in vitro cytotoxicity, and in vivo distribution of transferrin-bound cis-platinum(II) of differing molar ratios. J Control Release 1995;37:75-81
   Web of Science ®Google Scholar
• Beyer U, Roth T, Schumacher P, et al. Synthesis and in Vitro Efficacy of Transferrin Conjugates of the Anticancer Drug Chlorambucil. J Med Chem 1998;41:2701-8
   PubMed Web of Science ®Google Scholar
• Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8
   PubMed Web of Science ®Google Scholar
• Cirillo G, Kraemer K, Fuessel S, et al. Biological activity of a gallic acid-gelatin conjugate. Biomacromolecules 2010;11:3309-15
   PubMed Web of Science ®Google Scholar
• Cho YW, Park SA, Han TH, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 2007;28:1236-47
   PubMed Web of Science ®Google Scholar
• Matsumoto G, Kushibiki T, Kinoshita Y, et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci 2006;97:313-21
   PubMed Web of Science ®Google Scholar
• Inada S, Fujiwara H, Atsuji K, et al. Successful gene transfer into dendritic cells with cationized gelatin and plasmid DNA complexes via a phagocytosis-dependent mechanism. Anticancer Res 2006;26:1957-63
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Takada S, Anai S, et al. Enhanced efficacy of radiation sensitivity by controlled gene delivery of PTEN expression vector conjugated with cationized gelatin in prostate cancer cells. Mol Ther 2004;9:S321
   Google Scholar
• Schmid B, Chung DE, Warnecke A, et al. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 2007;18:702-16
   PubMed Web of Science ®Google Scholar
• Kratz F, Warnecke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002;45:5523-33
   PubMed Web of Science ®Google Scholar
• Chung DE, Kratz F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg Med Chem Lett 2006;16:5157-63
   PubMed Web of Science ®Google Scholar
• Graeser R, Chung DE, Esser N, et al. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int J Cancer 2008;122:1145-54
   PubMed Web of Science ®Google Scholar
• Elsadek B, Graeser R, Esser N, et al. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP). Prostate Cancer Prostatic Dis 2011;14:14-21
   PubMed Web of Science ®Google Scholar
• Kratz F, Mansour A, Soltau J, et al. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim) 2005;338:462-72
   PubMed Web of Science ®Google Scholar
• Abu Ajaj K, Graeser R, Fichtner I, et al. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 2009;64:413-18
   PubMed Web of Science ®Google Scholar
• Elsadek B, Graeser R, Esser N, et al. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434-44
   PubMed Web of Science ®Google Scholar
• Warnecke A, Kratz F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjug Chem 2003;14:377-87
   PubMed Web of Science ®Google Scholar
• Warnecke A, Fichtner I, Sass G, et al. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (Weinheim) 2007;340:389-95
   PubMed Web of Science ®Google Scholar
• Warnecke A, Fichtner I, Garmann D, et al. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjug Chem 2004;15:1349-59
   PubMed Web of Science ®Google Scholar
• Desai N. Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC. Nanomedicine 2007;3:339
   Web of Science ®Google Scholar
• Yeh TK, Lu Z, Wientjes MG, et al. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867-74
   PubMed Web of Science ®Google Scholar
• Ding D, Zhu Z, Liu Q, et al. Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors. Eur J Pharm Biopharm 2011;79:142-9
   PubMed Web of Science ®Google Scholar
• Shapira A, Davidson I, Avni N, et al. Beta-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm 2012;80:298-305
   PubMed Web of Science ®Google Scholar
• Mandal BB, Kundu SC. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery. Nanotechnology 2009;20:355101
   PubMed Web of Science ®Google Scholar
• Mcdaniel JR, Callahan DJ, Chilkoti A. Drug delivery to solid tumors by elastin-like polypeptides. Adv Drug Deliv Rev 2010;62:1456-67
   PubMed Web of Science ®Google Scholar
• Wang C, Ho PC, Lim LY. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm 2010;400:201-10
   PubMed Web of Science ®Google Scholar